Acutus Medical

Canaccord Genuity acts as Co-Manager for upsized US$182.6 million initial public offering of common stock by Acutus Medical, Inc.

Canaccord Genuity is pleased to announce that on August 10, 2020, it completed an upsized initial public offering of common stock for Acutus Medical, Inc. (NASDAQ: AFIB) (the “Company”). The Company issued a total of 10,147,058 shares of its common stock at a price to the public of $18.00 per share, at the top of the filing range of $16.00 to $18.00, and includes the full exercise of the underwriters’ overallotment option. The gross proceeds to the Company, before deducting the underwriting discounts and commissions and estimated offering expenses, were approximately $182.6 million. The Company intends to use the net proceeds from the offering to support commercial expansion, complete ongoing clinical trials, fund research and development activities and for working capital and general corporate purposes.

Canaccord Genuity acted as Co-Manager for the offering.

Acutus Medical, Inc. develops a range of tools for catheter-based ablation procedures to treat various arrhythmias. The Company’s solution offers a paradigm-shifting approach to mapping the drivers and maintainers of arrhythmias with unmatched speed and precision, addressing a primary unmet need in electrophysiology procedures.